Interactions between five candidate genes and antihypertensive drug therapy on blood pressure

被引:33
|
作者
Schelleman, H
Stricker, BHC
Verschuren, WMM
de Boer, A
Kroon, AA
de Leeuw, PW
Kromhout, D
Klungel, OH
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, RIVM, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands
[4] Univ Hosp Maastricht, Dept Internal Med, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands
[5] Natl Inst Publ Hlth & Environm, RIVM, Div Nutr & Consumer Safety, NL-3720 BA Bilthoven, Netherlands
来源
PHARMACOGENOMICS JOURNAL | 2006年 / 6卷 / 01期
关键词
pharmacogenetics; pharmacogenomics; antihypertensive drugs; candidate genes;
D O I
10.1038/sj.tpj.6500339
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Despite the availability of effective antihypertensive drugs, there is a large variation in response to these drugs. This study investigates whether polymorphisms in the angiotensin converting enzyme (I/D), angiotensinogen (M235T), alpha-adducin (G460W), angiotensin II type 1 receptor (1166A/C), or G protein beta(3)-subunit (825C/T) gene modify the mean difference in blood pressure levels among diuretics, beta-blockers, or ACE-inhibitors users. Data were used from the Doetinchem Cohort Study, and blood pressure data were collected from GPs (1987-1997). A marginal generalized linear model (GEE) was used to assess the gene-drug interaction on the mean difference in systolic/diastolic blood pressure. In total, 625 hypertensive individuals were included with a total of 5262 measurements of blood pressure. Only the interaction between diuretic use and the GNB3 825C/T polymorphism was significant (C allele versus TT systolic blood pressure (SBP): 4.33 mmHg [95% CI: 0.14-8.54]). Thus, the mean SBP level among diuretic users may be modified by the GNB3 825C/T polymorphism.
引用
收藏
页码:22 / 26
页数:5
相关论文
共 50 条
  • [31] HIGH BLOOD-PRESSURE - THE SEARCH FOR CANDIDATE GENES
    DODET, B
    BIOFUTUR, 1992, (109) : 41 - 43
  • [32] Candidate genes revisited in the genetics of hypertension and blood pressure
    Norihiro Kato
    Hypertension Research, 2013, 36 : 1032 - 1034
  • [33] EVALUATION OF ANTIHYPERTENSIVE THERAPY - DISCREPANCIES BETWEEN OFFICE AND AMBULATORY RECORDED BLOOD-PRESSURE
    WAEBER, B
    RUTSCHMANN, B
    NUSSBERGER, J
    BRUNNER, HR
    JOURNAL OF HYPERTENSION, 1991, 9 : S53 - S56
  • [34] Blood pressure control in patients initiating antihypertensive therapy
    Weycker, Derek
    Edelsberg, John
    Vincze, Gabor
    Levy, Drew Griffin
    Kartashov, Alex
    Oster, Gerry
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (02) : 169 - 176
  • [35] Timing of Antihypertensive Therapy and Circadian Blood Pressure Pattern
    Almirall, Jaume
    Martinez-Ocana, Juan C.
    Comas, Lurdes
    HYPERTENSION, 2009, 53 (06) : E41 - E41
  • [36] Effect of Combination Antihypertensive Therapy Central Blood Pressure
    Kislyak, O. A.
    Davidenko, M. N.
    Postnikova, S. L.
    Moiseeva, E. V.
    KARDIOLOGIYA, 2015, 55 (04) : 67 - +
  • [37] Are There Benefits of Antihypertensive Therapy Beyond Blood Pressure Lowering?
    Izzo, Joseph L., Jr.
    CURRENT HYPERTENSION REPORTS, 2010, 12 (06) : 440 - 447
  • [38] Effective antihypertensive therapy: Blood pressure control with moxonidine
    Prichard, BNC
    Graham, BR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 : S38 - S48
  • [39] Blood pressure measurement and antihypertensive therapy in acute stroke
    Panayiotou, BN
    Lloyd, M
    Fotherby, MD
    Crome, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 1998, 52 (03) : 162 - 164
  • [40] Are There Benefits of Antihypertensive Therapy Beyond Blood Pressure Lowering?
    Joseph L. Izzo
    Current Hypertension Reports, 2010, 12 : 440 - 447